Details of the Drug

General Information of Drug (ID: DM87XSN)

Drug Name

REGN-727

Synonyms

Alirocumab; Alirocumab); RENG-727; Anti-PCSK9 antibody (hypercholesterolemia), Regeneron/sanofi-aventis

Indication

Disease Entry	ICD 11	Status	REF
Familial hypercholesterolemia	5C80.00	Approved	[1]
Hypercholesterolaemia	5C80.0	Approved	[2]

ATC Code

C10AX14: REGN-727

C10AX: Other lipid modifying agents

C10A: LIPID MODIFYING AGENTS, PLAIN

C10: LIPID MODIFYING AGENTS

C: CARDIOVASCULAR SYSTEM

Drug Type

Antibody

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 17 - 20 days [3]
Metabolism: The drug is metabolized via the reticuloendothelial system []

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	TTBRG7E	PCSK9_HUMAN	Not Available	[4]

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification

05 Endocrine, nutritional or metabolic disease

Disease Class

ICD-11: 5A11 Type 2 diabetes mellitus

The Studied Tissue

Whole blood

The Studied Disease

Familial hypercholesterolemia [ICD-11:5A11]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	DTT	PCSK9	4.82E-02	-0.07	-0.3

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6744).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36.